Chimeric antigen receptors
AssigneeAnthrogenesis Corporation
InventorsStewart Abbot, Bitao Liang, Tianjian Li
Life of this patent
Estimating the term…
Abstract
Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
Claims80
A polypeptide comprising (i) a transmembrane domain from CTLA4 or PD-1, (ii) an intracellular domain of an endogenous protein expressed on the surface of lymphocytes that triggers the activation and/or proliferation of said lymphocytes, and (iii) an extracellular domain that binds to an antigen, wherein
- if the transmembrane domain is from CTLA4, the intracellular domain and extracellular domain of said polypeptide are not from CTLA4;
- and
- if the transmembrane domain is from PD-1, the intracellular domain and extracellular domain of said polypeptide are not from PD-1.
A T lymphocyte comprising a membrane-bound polypeptide, wherein said polypeptide comprises (i) a transmembrane domain from CTLA4 or PD-1 (Programmed Cell Death 1), (ii) an intracellular domain of an endogenous protein expressed on the surface of lymphocytes and that triggers the activation and/or proliferation of said lymphocytes, and (iii) an extracellular domain that binds to an antigen, wherein
- if the transmembrane domain is from CTLA4, the intracellular domain and extracellular domain of said polypeptide are not from CTLA4;
- and
- if the transmembrane domain is from PD-1, the intracellular domain and extracellular domain of said polypeptide are not from PD-1.
Dependencies are inferred from the claim text.